Literature DB >> 20798558

The significance of fibroblast growth factor receptor 2 expression in differentiation of hepatocellular carcinoma.

Norifumi Harimoto1, Kenichi Taguchi, Ken Shirabe, Eisuke Adachi, Yoshihisa Sakaguchi, Yasushi Toh, Takeshi Okamura, Hiroto Kayashima, Akinobu Taketomi, Yoshihiko Maehara.   

Abstract

Fibroblast growth factor receptors (FGFRs) have been reported to be involved in the progression of many cancers. The aim of this study is to clarify the significance of FGFR2 expression in the differentiation of hepatocellular carcinoma (HCC). One nodule-in-nodule HCC sample was obtained from a patient to analyze the different expression in well- to moderately differentiated HCC and poorly differentiated HCC using microarray technique. The expression of FGFR2 in 46 patients with surgically resected HCC was immunohistochemically examined and analyzed in relation to their clinicopathological factors. Fgfr2 was 4.7 times up-regulated in poorly differentiated HCC from a nodule-in-nodule sample. The high expression group was 16 cases and the low expression group was 30 cases. The high FGFR2 expression correlated significantly with a poor histological differentiation, a higher incidence of portal vein and a high level of alpha-fetoprotein. The overall survival rates and the disease-free survival rates in high expression were significantly worse than those in low. In conclusion, a high FGFR2 expression plays an important role in poor differentiation, portal vein invasion, high alpha-fetoprotein production, and poor prognosis. These data suggest that FGFR2 may be a potentially useful biological marker of tumor invasiveness in HCC as well as a novel molecular target for HCC. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20798558     DOI: 10.1159/000320463

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  25 in total

1.  Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma.

Authors:  Shi Liu; Jian Gong; Asahiro Morishita; Takako Nomura; Hisaaki Miyoshi; Joji Tani; Kiyohito Kato; Hirohito Yoneyama; Akihiro Deguchi; Hirohito Mori; Shima Mimura; Kei Nomura; Takashi Himoto; Kazushi Deguchi; Keiichi Okano; Kunihiko Izuishi; Yasuyuki Suzuki; Yoshio Kushida; Reiji Haba; Hisakazu Iwama; Tsutomu Masaki
Journal:  Exp Ther Med       Date:  2011-02-08       Impact factor: 2.447

2.  Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts.

Authors:  Anh Tran; Tong San Koh; Aldo Prawira; Rebecca Zhi Wen Ho; Thi Bich Uyen Le; Thanh Chung Vu; Septian Hartano; Xing Qi Teo; Way Cherng Chen; Philip Lee; Choon Hua Thng; Hung Huynh
Journal:  Mol Imaging Biol       Date:  2020-09-09       Impact factor: 3.488

3.  Biological evaluation of a novel sorafenib analogue, t-CUPM.

Authors:  Aaron T Wecksler; Sung Hee Hwang; Jun-Yan Liu; Hiromi I Wettersten; Christophe Morisseau; Jian Wu; Robert H Weiss; Bruce D Hammock
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-21       Impact factor: 3.333

4.  18F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib.

Authors:  Yusuke Kawamura; Masahiro Kobayashi; Junichi Shindoh; Yuta Kobayashi; Kayoko Kasuya; Tomoya Sano; Shunichiro Fujiyama; Tetsuya Hosaka; Satoshi Saitoh; Hitomi Sezaki; Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Kenji Ikeda; Yasuji Arase; Masaji Hashimoto; Hiromitsu Kumada
Journal:  Liver Cancer       Date:  2019-11-13       Impact factor: 11.740

5.  Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.

Authors:  Daiki Yamashige; Yusuke Kawamura; Masahiro Kobayashi; Junichi Shindoh; Yuta Kobayashi; Satoshi Okubo; Nozomu Muraishi; Akira Kajiwara; Soichi Iritani; Shunichiro Fujiyama; Tetsuya Hosaka; Satoshi Saitoh; Hitomi Sezaki; Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Kenji Ikeda; Yasuji Arase; Masaji Hashimoto; Hiromitsu Kumada
Journal:  Oncology       Date:  2020-11-18       Impact factor: 2.935

6.  Emodin regulating excision repair cross-complementation group 1 through fibroblast growth factor receptor 2 signaling.

Authors:  Gang Chen; Hong Qiu; Shan-Dong Ke; Shao-Ming Hu; Shi-Ying Yu; Sheng-Quan Zou
Journal:  World J Gastroenterol       Date:  2013-04-28       Impact factor: 5.742

7.  The influence of histological differentiation grade on the outcome of liver resection for hepatocellular carcinomas 2 cm or smaller in size.

Authors:  Kazunari Sasaki; Masamichi Matsuda; Yu Ohkura; Yusuke Kawamura; Masafumi Inoue; Masaji Hashimoto; Kenji Ikeda; Hiromitsu Kumada; Goro Watanabe
Journal:  World J Surg       Date:  2015-05       Impact factor: 3.352

8.  In hepatocellular carcinomas, any proportion of poorly differentiated components is associated with poor prognosis after hepatectomy.

Authors:  Kazunari Sasaki; Masamichi Matsuda; Yu Ohkura; Yusuke Kawamura; Masafumi Inoue; Masaji Hashimoto; Kenji Ikeda; Hiromitsu Kumada; Goro Watanabe
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

9.  The fibroblast growth factor receptor 2-mediated extracellular signal-regulated kinase 1/2 signaling pathway plays is important in regulating excision repair cross-complementary gene 1 expression in hepatocellular carcinoma.

Authors:  Gang Chen; Hong Qiu; Shandong Ke; Shaoming Hu; Shiying Yu; Shengquan Zou
Journal:  Biomed Rep       Date:  2013-04-19

10.  Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis.

Authors:  Yusuke Kawamura; Masahiro Kobayashi; Junichi Shindoh; Yuta Kobayashi; Kayoko Kasuya; Tomoya Sano; Shunichiro Fujiyama; Tetsuya Hosaka; Satoshi Saitoh; Hitomi Sezaki; Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Kenji Ikeda; Yasuji Arase; Masaji Hashimoto; Hiromitsu Kumada
Journal:  Liver Cancer       Date:  2020-02-04       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.